Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The first GLP-1 receptor agonist approved by the FDA, originally derived from Gila monster saliva. Available in twice-daily (Byetta) and once-weekly (Bydureon) formulations. Paved the way for semaglutide and tirzepatide.
A once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes. Shorter-acting than semaglutide, with a stronger effect on postprandial glucose. Also available in a fixed-ratio combination with insulin glargine (Soliqua).
Synthetic version of exendin-4, a peptide found in Gila monster venom that shares 53% homology with human GLP-1 but resists DPP-4 degradation. Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
Activates GLP-1 receptors, stimulating glucose-dependent insulin secretion and suppressing glucagon. Its shorter duration of action produces a more pronounced effect on gastric emptying and postprandial glucose compared to longer-acting GLP-1 agonists.
- Type 2 diabetes
- Blood sugar regulation
- Modest weight loss
- Type 2 diabetes (adjunct to diet and exercise)
- Postprandial glucose control
- Combined with basal insulin (Soliqua)
- Nausea (common, especially initially)
- Pancreatitis (rare)
- Injection site nodules (Bydureon)
- Renal impairment
- Thyroid C-cell tumors (animal studies)
- Nausea and vomiting (common, usually transient)
- Diarrhea
- Headache
- Hypoglycemia when combined with sulfonylureas
- Pancreatitis (rare)
FDA-approved as Byetta (2005, twice daily) and Bydureon (2012, once weekly). The first-in-class GLP-1 agonist. Largely superseded by semaglutide for new prescriptions but still widely used.
FDA-approved as Adlyxin (2016) for type 2 diabetes. Also available as Soliqua 100/33 (fixed-ratio combination with insulin glargine). Less weight loss than semaglutide but better postprandial control.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.